Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Reed Johnson

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Journal of Neurology|May 16, 2009
Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacyF Reed Johnson, George Van Houtven, Semra Ozdemir, et al.
Vaccine|August 26, 2011
Healthy-days time equivalents for outcomes of acute rotavirus infectionsA Brett Hauber, Robbin Itzler, F Reed Johnson, et al.
The Patient|November 9, 2021
Women's Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During PregnancyTatyana Kushner, Angelyn Fairchild, F Reed Johnson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time EquivalentsMeenakshi Bewtra, Shelby D Reed, F Reed Johnson, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Patient Engagement at a Tipping Point-The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders: Insights From the DIA Conference, "Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products"Meredith Y Smith, Tarek A Hammad, Marilyn Metcalf, et al.
Alzheimer Disease and Associated Disorders|August 30, 2008
Older Americans' risk-benefit preferences for modifying the course of Alzheimer diseaseA Brett Hauber, F Reed Johnson, Howard Fillit, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task ForceJohn F P Bridges, A Brett Hauber, Deborah Marshall, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2009
Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndromeLarry D Lynd, Mehdi Najafzadeh, Lindsey Colley, et al.
The American Journal of Gastroenterology|April 17, 2025
Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel DiseaseJui-Chen Yang, Ellen M Janssen, Matthew J Wallace, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2013
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task ForceF Reed Johnson, Emily Lancsar, Deborah Marshall, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Journal of Neurology|May 16, 2009
Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacyF Reed Johnson, George Van Houtven, Semra Ozdemir, et al.
Vaccine|August 26, 2011
Healthy-days time equivalents for outcomes of acute rotavirus infectionsA Brett Hauber, Robbin Itzler, F Reed Johnson, et al.
The Patient|November 9, 2021
Women's Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During PregnancyTatyana Kushner, Angelyn Fairchild, F Reed Johnson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time EquivalentsMeenakshi Bewtra, Shelby D Reed, F Reed Johnson, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Patient Engagement at a Tipping Point-The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders: Insights From the DIA Conference, "Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products"Meredith Y Smith, Tarek A Hammad, Marilyn Metcalf, et al.
Alzheimer Disease and Associated Disorders|August 30, 2008
Older Americans' risk-benefit preferences for modifying the course of Alzheimer diseaseA Brett Hauber, F Reed Johnson, Howard Fillit, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task ForceJohn F P Bridges, A Brett Hauber, Deborah Marshall, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2009
Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndromeLarry D Lynd, Mehdi Najafzadeh, Lindsey Colley, et al.
The American Journal of Gastroenterology|April 17, 2025
Quantifying Patient Preferences for Risk Tolerance With Novel Dual Biologic Therapies for Inflammatory Bowel DiseaseJui-Chen Yang, Ellen M Janssen, Matthew J Wallace, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2013
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task ForceF Reed Johnson, Emily Lancsar, Deborah Marshall, et al.
Pageof 12